Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-20T02:47:29.914Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuroleptic Malignant Syndrome Secondary to Loxapine

Published online by Cambridge University Press:  02 January 2018

L. S. Chong  and
P. M. Abbott
L. S. Chong*
Affiliation:
Fazakerley Hospital, Longmoor Lane, Liverpool L9 7AL
P. M. Abbott
Affiliation:
Sefton General Hospital, Liverpool L15 2HE
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

Loxapine was introduced to the British market two years ago although it has been used in North America for eight years. We report the first probable case of neuroleptic malignant syndrome (NMS) secondary to loxapine in Britain. Two previous cases have been reported in North America (manufacturer's data).

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 159 , Issue 4 , October 1991 , pp. 572 - 573
Copyright
Copyright © 1991 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Caroff, S. N. (1980) The neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 41, 79–83.Google Scholar
Kellam, A. M. P. (1987) The neuroleptic malignant syndrome, so-called. A survey of the world literature. British Journal of Psychiatry, 150, 752–759.Google Scholar
Shalev, A. & Munitz, H. (1986) The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatrica Scandinavica, 73, 337–347.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.